No. 20-1258

Ono Pharmaceutical Co., Ltd., et al. v. Dana-Farber Cancer Institute, Inc.

Lower Court: Federal Circuit
Docketed: 2021-03-11
Status: Denied
Type: Paid
Experienced Counsel
Tags: conception conception-standard federal-circuit-rule inventorship-correction joint-inventorship non-obviousness novelty patent-law prior-art
Key Terms:
Patent
Latest Conference: 2021-05-20
Question Presented (AI Summary)

Whether the Federal Circuit erred in adopting a bright-line rule that the novelty and non-obviousness of an invention over alleged contributions that were already in the prior art are 'not probative' of whether those alleged contributions were significant to conception

Question Presented (OCR Extract)

QUESTION PRESENTED Section 116 of title 35 provides that “when an invention is made by two or more persons jointly, they shall apply for a patent jointly.” A person who claims to have been improperly omitted from the list of inventors on a patent may bring a cause of action for correction of inventorship under 35 U.S.C. § 256. The Federal Circuit has held that “to be a joint inventor, an individual must make a contribution to the conception of the claimed invention that is not insignificant in quality, when that contribution is measured against the dimension of the full invention.” Fina Oil & Chem. Co. v. Ewen, 123 F.3d 1466, 1473 (Fed. Cir. 1997). In this case, in conflict with this Court’s guidance and the Fourth Circuit, the Federal Circuit adopted a bright-line rule that the novelty and non-obviousness of an invention over alleged contributions that were already in the prior art are not probative of whether those alleged contributions were significant to conception. App. 18a. The question presented is: Whether the Federal Circuit erred in adopting a bright-line rule that the novelty and non-obviousness of an invention over alleged contributions that were already in the prior art are “not probative” of whether those alleged contributions were significant to conception. @

Docket Entries

2021-05-24
Petition DENIED. Justice Breyer took no part in the consideration or decision of this petition.
2021-05-04
DISTRIBUTED for Conference of 5/20/2021.
2021-05-03
Reply of petitioners Ono Pharmaceutical Co., Ltd.,, et al. filed. (Distributed)
2021-04-20
Brief of respondent Dana-Farber Cancer Institute, Inc. in opposition filed.
2021-04-07
Motion to extend the time to file a response is granted and the time is extended to and including April 20, 2021.
2021-04-05
Motion to extend the time to file a response from April 12, 2021 to April 20, 2021, submitted to The Clerk.
2021-03-08
Petition for a writ of certiorari filed. (Response due April 12, 2021)

Attorneys

Dana-Farber Cancer Institute, Inc.
Donald R. WareFoley Hoag LLP, Respondent
Donald R. WareFoley Hoag LLP, Respondent
Ono Pharmaceutical Co., Ltd.,, et al.
Seth P. WaxmanWilmer Cutler Pickering Hale and Dorr LLP, Petitioner
Seth P. WaxmanWilmer Cutler Pickering Hale and Dorr LLP, Petitioner